



Using Technology to Improve Medication Adherence for Cardiometabolic Disorders

Contributing authors on behalf of Team Best Practices:


Sarah Aldrich Renner, PharmD, BCACP, University of Toledo
James J. Werner, PhD, MSSA, Case Western Reserve University
Karen Bailey, MS, RDN, LD, CDCES, Ohio University
Amber Healy, DO, Ohio University
Mary Beth Vonder Meulen, RN, CCRc, University of Cincinnati
Hollie Goodell, RN, Ohio University
Susan Schrimpf Davis, DO, University of Cincinnati

Medication adherence is the extent to which a person's medication-taking behavior corresponds with agreed upon treatment recommendations from a health care provider.¹

Medication nonadherence has been defined as taking either less than 80% or more than prescribed doses.² An estimated 30% to 50% of medications for chronic diseases are not taken as prescribed,³⁻⁵ and this can result in needlessly escalated treatments, potential harm to patients, and increased health care costs.⁶ In the treatment of cardiometabolic disorders, nonadherence is a significant problem.⁷⁻⁹


Five dimensions of medication adherence are widely recognized as contributing factors: patient-related, medication-related, condition-related, health care system/health care provider-related, and socioeconomic.¹⁰ Nonadherence is associated with internal and external factors, including regimen complexity, polypharmacy, cognitive and functional decline, cost and access, inadequate social support, and lack of needed assistance in taking medication.^{11,12}

It can be difficult for providers to recognize nonadherence, and interventions can be time-intensive with mixed results.^{1,13,14} Non-technological behavioral and educational interventions have been shown to improve medication adherence compared with usual care.¹¹ Digital technologies, such as devices and mobile health applications (apps), can provide medication reminders, track medication use, and increase patients' understanding of how to manage chronic health conditions. When selected and implemented in close collaboration with patients, these technologies have the potential to improve patients' health-related knowledge and medication-taking behaviors, thereby improving adherence.¹⁵



Types of Tools Available

- **Smart pill bottles**^{10,16} track when medications are taken and send reminders to patients when it is time to take the next dose. Some models can send alerts to caregivers or health care providers if medication doses are missed.
 - **Medication Event Monitoring System (MEMS):** uses electronic caps on medication bottles to record date and time when the pill bottle is opened.¹⁷
 - **Smart blister packaging:** medication packaging, similar to regular adherence packaging but records dates and times when doses are taken.
- **Electronic pill dispensers** dispense medications at specific times and can be programmed to send reminders to patients when it is time to take medications. Features may include recording the date and time when the container was opened, visual/audible alerts¹⁸ alerting a caregiver of missed doses, or custom messaging. Some devices combine the dispenser functions with fall detection alerts and emergency alerts. Caregiver subscription to an online app may be required. Some systems work with pharmacies to fill and track medications.¹⁹⁻²¹
- **Smart Sharps Bins**TM use sensors to monitor used syringes and needles being deposited into the sharps container. The bins may include visual/audible reminders or even work online to help track and manage injectable medications.²² This type of “smart” container may help to monitor patient compliance with self-injection of medication, a critical part of older adult self-care and caregiving.
- **Smart insulin pens** are reusable insulin pens or devices (e.g., pen caps, buttons) available only by prescription that are connected online to help calculate medication dosage and track times of injections in patients taking multiple daily doses of insulin. Some pens offer dose calculation based on settings (e.g., carbohydrate ratio and correction factor) programmed by the health care provider. Newer smart pens are connected to continuous glucose monitoring systems (CGMs) and reports can be viewed on a phone or electronic device. Health care providers can download reports to help with reprogramming dose adjustments based a patient’s glucose patterns.²³ It has been reported that smart pens and pen caps improve medication adherence and improve patient confidence with insulin dosing.^{24,25} See [Appendix, Table 1](#) for examples.
- **Glucose measuring devices** consist of a minimally invasive subcutaneous interstitial glucose sensor connected to a transmitter that is worn on the body.^{26,27} The transmitter sends glucose readings to a receiver (a reader or online app), which translates the interstitial glucose to a blood glucose and is viewable by the wearer. These devices (e.g., Dexcom G6 and G7, FreeStyle Libre 2 and 3, Eversense®) show the patient sensor readings every 1 to 5 minutes, 24 hours per day, allowing the patient and provider to evaluate the glucose response to various meals, snacks, physical activity, stress, and illness. CGM use is associated with lower HbA1c, improved percentage of time in range (defined as 70 mg/dL-180 mg/dL), higher



patient satisfaction, and reduced risk of diabetes-related hospitalizations.²⁸⁻³² The patient can receive alarms for high and low glucose levels. Glucose reports can be reviewed by the provider online or downloaded by staff in the office and as part of remote monitoring. Finally, mobile apps can be linked to the clinic, so that reports can be reviewed in real time by the provider.


- **Glucometers** can link with a variety of mobile apps that can be helpful in keeping track of blood glucose readings, provide reminders to patients to check blood glucose, and generate reports. Mobile apps (e.g., OneTouch Reveal®, mySugr, BD™ Diabetes Care) can share reports with providers for review. Additionally, there are apps that can collect and combine data from insulin pumps, glucometers, and fitness trackers into one report (e.g., Glooko, Tidepool).



- **Insulin pumps** use artificial intelligence to regulate insulin delivery based on connected CGM data, trends, and insulin delivery histories. The pumps can be paired with mobile apps (e.g., Medtronic MiniMed® Mobile app to professional CareLink™ account, t:connect mobile app to professional t:connect portal [soon to be Tandem Source], Omnipod® 5 app to professional Glooko account) that can stream data to web-based professional accounts and be viewed by providers in the office.




- **Smart blood pressure monitors**,²⁷ either blood pressure monitors or blood pressure cuffs, may be used at home by individuals with hypertension or other cardiovascular conditions to measure their blood pressure regularly. Evidence supports the use of home blood pressure monitoring to improve antihypertensive medication adherence and improve blood pressure management.²⁷ Patients who are prescribed home blood pressure monitors may receive coverage or reimbursement from their insurance provider. Some of these devices (e.g., OMRON, Withings, iHealth, QardioArm, Oxiline, A&D Medical) have features such as Bluetooth connectivity to sync data with mobile apps to allow data tracking and analysis.



- **Mobile Apps**³³

- **Medisafe Medication** allows users to track their medications and set reminders to take them. It also provides information about possible drug interactions and side effects. Users can import prescriptions from major chain pharmacies and add over the counter medications manually, keep track of refills, get coupons, and access resources on medical conditions.
- **MyTherapy** offers a medication tracker and reminder feature, as well as a symptom tracker and a health journal. It also provides patients with medication information and allows them to share their medication history with healthcare professionals.
- **MyMedSchedule** helps patients create a personalized medication schedule and set reminders to take their medications. It also provides educational resources about different medications.
- **Round Health** allows patients to create a visual list of their medications and set reminders to take them. It also provides information about potential drug interactions and side effects.




Implementation of Technology to Improve Medication Adherence

The Identify, Configure, Collaborate (ICC) Framework:³⁴

The ICC Framework offers health care providers a standardized approach to helping patients choose, use, and benefit from the use of technologies. When implemented in collaboration with patients, this approach may help to improve adoption rates of adherence-enhancing digital technologies.

Figure 1. Identify, Configure, Collaborate (ICC) Framework⁵



Adapted from A Framework for Optimizing Technology-Enabled Diabetes and Cardiometabolic Care and Education: The Role of the Diabetes Care and Education Specialist.

Considerations for Prescribing Technology to Improve Medication Adherence

There is minimal evidence demonstrating specific improvement in adherence with the technology examples listed above. Also, due to their recent emergence, some technologies have not yet been compared with existing approaches to improving adherence or utilized across a range of populations.

Even considering the potential of improved medication adherence, patient-specific factors should be considered before recommending new devices. These factors include insurance coverage, out-of-pocket costs, support networks, usability, complexity, internet access, additionally required technology (e.g., smart phone), and time.²² Also, certain populations, such as older adults, those with financial barriers or low health literacy, or those with limited access to health care, may be less likely to use health information technology.^{35,36} For example, literacy-related disparities in technology access and use are widespread. Instructions may be complex and require comprehensive education prior to use.²⁵ Although providers and patient's often view barriers differently,³⁷ providers can mitigate patient concerns by assessing the user's digital skills and literacy level, providing plainly worded instructions (augmented with illustrations), providing direct assistance with set up, and ensuring that ongoing support networks will be available.³⁸ Other techniques, such as shared decision making and motivational interviewing may also help.

With all their potential, innovations designed to improve medication adherence are evolving, and products may be made available despite limited evidence to support their effectiveness. Technological interventions vary in the aspects of adherence they address, so tailored combinations of technological and non-technological interventions may be indicated. Ultimately, technology holds promise for the improvement of medication adherence, but it's use is more likely to help when providers 1) assess patient need, 2) review usability, and 3) consider technology as one component of a plan to improve medication taking.³⁴

Access Cardi-OH's Expanded Resources

- **Addressing Common Barriers to Insulin Initiation and Use**
cardi-oh.org/resources/addressing-common-barriers-to-insulin-initiation-and-use
- **Medication Adherence: The Key to Positive Patient Outcomes**
cardi-oh.org/resources/medication-adherence-the-key-to-positive-patient-outcomes
- **One Simple Step to Improve Medication Adherence for Blood Pressure Control (Capsule 1)**
cardi-oh.org/resources/capsule-1--one-simple-step-to-improve-medication-adherence-for-blood-pressure-control
- **Ohio Department of Medicaid: Checking Your Blood Pressure at Home**
cardi-oh.org/resources/ohio-department-of-medicaid-checking-your-blood-pressure-at-home
- **Optimizing the Telehealth Diabetes Visit: Glucose Monitoring Data**
cardi-oh.org/resources/optimizing-the-telehealth-diabetes-visit-glucose-monitoring-data
- **Overcoming the Digital Divide**
cardi-oh.org/resources/overcoming-the-digital-divide
- **Simplified Prescription of Diabetes Technology and Medications (Capsule 25)**
cardi-oh.org/resources/capsule-25--simplified-prescription-of-diabetes-technology-and-medications

References

1. World Health Organization (WHO). Adherence to long-term therapies: evidence for action. *Ann Saudi Med.* 2004;24(3):221-222. doi:10.5144/0256-4947.2004.221.
2. Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. *Cochrane Database Syst Rev.* 2014;2014(11):CD000011. doi:10.1002/14651858.CD000011.pub4.
3. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. *Pharmacotherapy.* 2008;28(4):437-443. doi:10.1592/phco.28.4.437.
4. Foley L, Larkin J, Lombard-Vance R, et al. Prevalence and predictors of medication non-adherence among people living with multimorbidity: a systematic review and meta-analysis. *BMJ Open.* 2021;11(9):e044987. doi:10.1136/bmjopen-2020-044987.
5. Osterberg L, Blaschke T. Adherence to medication. *N Engl J Med.* 2005;353(5):487-497. doi:10.1056/NEJMra050100.
6. Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. *Health Aff (Millwood).* 2011;30(1):91-99. doi:10.1377/hlthaff.2009.1087.
7. Yang Y, Thumula V, Pace PF, et al. Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: a retrospective cohort study. *Clin Ther.* 2009;31(10):2178-2188. doi:10.1016/j.clinthera.2009.10.002.
8. Peacock E, Craig LS, Krousel-Wood M. Electronic health strategies to improve medication adherence in patients with cardiometabolic disease: current status and future directions. *Curr Opin Cardiol.* 2022;37(4):307-316. doi:10.1097/HCO.0000000000000971.
9. Ferdinand KC, Yadav K, Nasser SA, et al. Disparities in hypertension and cardiovascular disease in blacks: the critical role of medication adherence. *J Clin Hypertens (Greenwich).* 2017;19(10):1015-1024. doi:10.1111/jch.13089.
10. Ellsworth GB, Burke LA, Wells MT, et al. Randomized pilot study of an advanced smart-pill bottle as an adherence intervention in patients with HIV on antiretroviral treatment. *J Acquir Immune Defic Syndr.* 2021;86(1):73-80. doi:10.1097/QAI.0000000000002519.
11. Cross AJ, Elliott RA, Petrie K, et al. Interventions for improving medication-taking ability and adherence in older adults prescribed multiple medications. *Cochrane Database Syst Rev.* 2020;5(5):CD012419. doi:10.1002/14651858.CD012419.pub2.
12. Vik SA, Hogan DB, Patten SB, et al. Medication nonadherence and subsequent risk of hospitalisation and mortality among older adults. *Drugs Aging.* 2006;23(4):345-356. doi:10.2165/00002512-200623040-00007.
13. Peng Y, Wang H, Fang Q, et al. Effectiveness of Mobile Applications on Medication Adherence in Adults with Chronic Diseases: A Systematic Review and Meta-Analysis. *J Manag Care Spec Pharm.* 2020;26(4):550-561. doi:10.18553/jmcp.2020.26.4.550.
14. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. *Am J Med.* 2012;125(9):882-887.e1. doi:10.1016/j.amjmed.2011.12.013.
15. Zomahoun HTV, Guénette L, Grégoire JP, et al. Effectiveness of motivational interviewing interventions on medication adherence in adults with chronic diseases: a systematic review and meta-analysis. *Int J Epidemiol.* 2017;46(2):589-602. Doi:10.1093/ije/dyw273.
16. Mauro J, Mathews KB, Sredzinski ES. Effect of a smart pill bottle and pharmacist intervention on medication adherence in patients with multiple myeloma new to lenalidomide therapy. *J Manag Care Spec Pharm.* 2019;25(11):1244-1254. doi:10.18553/jmcp.2019.25.11.1244.
17. Abbott, A: CARE Pro. Looking into the crystal-ball: Advances in technology for improving adherence. <https://acarepro.abbott.com/articles/general-topics/future-technological-interventions-medication-adherence/>. Accessed December 1, 2023.
18. Treskes RW, Van der Velde ET, Schoones JW, Schaliij MJ. Implementation of smart technology to improve medication adherence in patients with cardiovascular disease: is it effective? *Expert Rev Med Devices.* 2018;15(2):119-126. doi:10.1080/17434440.2018.1421456.
19. Mason M, Cho Y, Rayo J, et al. Technologies for medication adherence monitoring and technology assessment criteria: narrative review. *JMIR Mhealth Uhealth.* 2022;10(3):e35157. doi:10.2196/35157.
20. Langendoen-Gort M, Al-Jabr H, Hugtenburg JG, et al. A personalised intervention programme aimed at improving adherence to oral antidiabetic and/or antihypertensive medication in people with type 2 diabetes mellitus, the INTENSE study: study protocol for a randomised controlled trial. *Trials.* 2022;23(1):731. doi:10.1186/s13063-022-06491-7.
21. Patel T, Ivo J, Faisal S, et al. A prospective study of usability and workload of electronic medication adherence products by older adults, caregivers, and health care providers. *J Med Internet Res.* 2020;22(6):e18073. doi:10.2196/18073.
22. Smart Sharps Bin. <https://smartsharpsbin.com/>. Accessed October 23, 2023.
23. American Diabetes Association. About Diabetes: What is a smart insulin pen? <https://diabetes.org/tools-support/devices-technology/smart-insulin-pen>. Accessed October 26, 2023.
24. Ospelt E, Noor N, Sanchez J, et al. Facilitators and barriers to smart insulin pen use: a mixed-method study of multidisciplinary stakeholders from diabetes teams in the United States. *Clin Diabetes.* 2022;41(1):56-67. doi:10.2337/cd22-0068.
25. Galindo RJ, Ramos C, Cardona S, et al. Efficacy of a smart insulin pen cap for the management of patients with uncontrolled type 2 diabetes: a randomized cross-over trial. *J Diabetes Sci Technol.* 2023;17(1):201-207. doi:10.1177/19322968211033837.
26. Association of Diabetes Care & Education Specialists. Danatech Diabetes Technology. <https://www.adces.org/danatech/home>. Accessed on April 22, 2024.
27. Riegel B, Moser DK, Buck HG, et al. Self-care for the prevention and management of cardiovascular disease and stroke: a scientific statement for healthcare professionals from the American Heart Association. *J Am Heart Assoc.* 2017;6(9):e006997. doi:10.1161/JAHA.117.006697.

28. Yaron M, Roitman E, Aharon-Hananel G, et al. Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes. *Diabetes Care*. 2019;42(7):1178-1184. doi:10.2337/dc18-0166.
29. Martens T, Beck RW, Bailey R, et al. Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. *JAMA*. 2021;325(22):2262-2272. doi:10.1001/jama.2021.7444.
30. Gilbert TR, Noar A, Blalock O, Polonsky WH. Change in hemoglobin A1c and quality of life with real-time continuous glucose monitoring use by people with insulin-treated diabetes in the Landmark Study. *Diabetes Technol Ther*. 2021;23(S1):S35-S39. doi:10.1089/dia.2020.0666.
31. Bergenstal RM, Kerr MSD, Roberts GJ, et al. Flash CGM is associated with reduced diabetes events and hospitalizations in insulin-treated type 2 diabetes. *J Endocr Soc*. 2021;5(4):bvab013. doi:10.1210/jendso/bvab013.
32. Roussel R, Riveline JP, Vicaut E, et al. Important Drop in Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The RELIEF Study. *Diabetes Care*. 2021;44(6):1368-1376. doi:10.2337/dc20-1690.
33. Garrett P, Brown CA, Hart-Hester S, et al. Identifying barriers to the adoption of new technology in rural hospitals: a case report. *Perspect Health Inf Manag*. 2006;3:9.
34. Greenwood DA, Howell F, Scher L, et al. A framework for optimizing technology-enabled diabetes and cardiometabolic care and education: the role of the diabetes care and education specialist. *Diabetes Educ*. 2020;46(4):315-322. doi:10.1177/0145721720935125.
35. Bailey SC, O'Connor R, Bojarski EA, et al. Literacy disparities in patient access and health-related use of Internet and mobile technologies. *Health Expect*. 2015;18(6):3079-3087. doi:10.1111/hex.12294.
36. Panahi S, et al. Patient adherence to health care provider recommendations and medication among free clinic patients. *J Patient Exp*. 2022; 9: 23743735221077523. doi: 10.1177/23743735221077523
37. Stirratt MJ, Curtis JR, Danila MI, et al. Advancing the science and practice of medication adherence. *J Gen Intern Med*. 2018;33(2):216-222. doi:10.1007/s11606-017-4198-4.
38. Smith S, Ayuk V, Scalzo P. Barriers to technology adoption by patients and providers in diabetes and hypertension care management. *Digital Medicine and Healthcare Technology*. 2023. doi:10.5772/dmht.18.

Appendix

Table 1. Smart Pens and Pen Caps

| Device | pen/ cap/ button | CGMs/BGM Compatibility | Compatible Insulin | Cartridge (Yes/No) | Dose Calculation | Associated Apps | Other features | More information |
|-----------------------|--------------------------------|-------------------------------|--------------------------------|--------------------|------------------|--------------------------|---|--|
| Bigfoot Unity® | cap | Freestyle Libre (CGM) | Rapid acting insulin | No | Able | Bigfoot Unity Mobile app | White cap for rapid insulin; black cap for long-acting insulin; works with prefilled pen | bigfootbiomedical.com/bigfoot-unity |
| | | Bigfoot Glucose Monitor (BGM) | Humalog Kwikpen (U-100, U-200) | | | | | |
| | | | Lyumjev Kwikpen (U-100, U-200) | | | | | |
| | | | Insulin lispro Kwikpen | | | | | |
| | | | Apidra Solostar | | | | | |
| | | | Admelog Solostar | | | | | |
| | | | Novolog Flexpen | | | | | |
| | | | Fiasp Flexpen | | | | | |
| | | | Relion Novolog Flexpen | | | | | |
| | | | Insulin aspart Flexpen | | | | | |
| | | | Long acting insulin | | | | | |
| | | | Basaglar Kwikpen | | | | | |
| | | | Lantus Solostar | | | | | |
| | Toujeo Solostar (U-300) | | | | | | | |
| | Tresiba Flextouch (U100, U200) | | | | | | | |
| In Pen® | pen | Dexcom (CGM) | Humalog | Yes | Able | In Pen app | Reusable pen; insulin dosing in 0.5 unit increments, max dose per injection 30 units | medtronicdiabetes.com/products/inpen-smart-insulin-pen-system |
| | | Guardian Connect (CGM) | Novolog | | | | | |
| Novo Pen Echo® | pen | Not available in US | Novolog | Yes | Unable | None | Reusable pen; memory capacity; insulin dosing 0.5 unit increments; max dose per injection 30 units | novonordisk.com/our-products/pens-and-needles/novopen-echo.html |
| | | | Fiasp | | | | | |
| | | | | | | | | |
| Tempo® pen | pen | Dexcom (CGM) | Rapid acting insulin | No | Unable | Tempo Smart app | Pre-filled pen; re-usable button; button lasts 8 months; same button can be used for both basal and bolus insulin | lillytempo.com |
| | | Tempo (BGM) | Humalog | | | | | |
| | | Accu-Chek Aviva (BGM) | Lyumjev | | | | | |
| | | Accu-Chek Guide (BGM) | Long acting insulin | | | | | |
| | | Accu-Chek Instant (BGM) | Basaglar | | | | | |
| | | One Touch Verio Reflect (BGM) | | | | | | |
| | | One Touch Verio Flex (BGM) | | | | | | |
| True Metrix Air (BGM) | | | | | | | | |

Partners



In partnership with



The Ohio Cardiovascular & Diabetes Health Collaborative is funded by the Ohio Department of Medicaid and administered by the Ohio Colleges of Medicine Government Resource Center. The views expressed in this document are solely those of the authors and do not represent the views of the state of Ohio or federal Medicaid programs.